Waylan K Bessler
Overview
Explore the profile of Waylan K Bessler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
556
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mitchell D, Brewster K, Makri S, Khan J, Albright E, Horvai A, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40063513
Purpose: MPNST is the leading cause of premature death among individuals with NF1 and the transcriptional aberrations that precede malignant transformation and contribute to MPNST tumorigenesis remain poorly defined. Alterations...
2.
Chang L, Oblinger J, Smith A, Ferrer M, Angus S, Hawley E, et al.
PLoS One
. 2021 Jul;
16(7):e0252048.
PMID: 34264955
Neurofibromatosis Type 2 (NF2) is an autosomal dominant genetic syndrome caused by mutations in the NF2 tumor suppressor gene resulting in multiple schwannomas and meningiomas. There are no FDA approved...
3.
Laurent D, Smith A, Bessler W, Mendonca M, Chin-Sinex H, Descovich M, et al.
Neurooncol Adv
. 2021 Jun;
3(1):vdab063.
PMID: 34131650
Background: Genetically susceptible individuals can develop malignancies after irradiation of normal tissues. In the context of therapeutic irradiation, it is not known whether irradiating benign neoplasms in susceptible individuals promotes...
4.
Fisher M, Shih C, Rhodes S, Armstrong A, Wolters P, Dombi E, et al.
Nat Med
. 2021 Jan;
27(1):165-173.
PMID: 33442015
Neurofibromatosis type 1 (NF1) plexiform neurofibromas (PNs) are progressive, multicellular neoplasms that cause morbidity and may transform to sarcoma. Treatment of Nf1;Postn-Cre mice with cabozantinib, an inhibitor of multiple tyrosine...
5.
Mund J, Park S, Smith A, He Y, Jiang L, Hawley E, et al.
J Biol Chem
. 2020 Nov;
295(46):15795.
PMID: 33188083
No abstract available.
6.
Mund J, Park S, Smith A, He Y, Jiang L, Hawley E, et al.
J Biol Chem
. 2020 May;
295(29):9948-9958.
PMID: 32471868
Neurofibromatosis type 1 (NF1) is a common cancer predisposition syndrome caused by mutations in the tumor suppressor gene. encodes neurofibromin, a GTPase-activating protein for RAS proto-oncogene GTPase (RAS). Plexiform neurofibromas...
7.
Burks C, Rhodes S, Bessler W, Chen S, Smith A, Gehlhausen J, et al.
Mol Cancer Ther
. 2019 Sep;
18(12):2321-2330.
PMID: 31527226
Neurofibromatosis Type 1 (NF1) is one of the most common genetic tumor predisposition syndromes in humans. Mutant results in dysregulated RAS allowing neoplasms throughout the neuroaxis. Plexiform neurofibromas (pNF) afflict...
8.
Bessler W, Hudson F, Zhang H, Harris V, Wang Y, Mund J, et al.
Free Radic Biol Med
. 2016 Jun;
97:212-222.
PMID: 27266634
Neurofibromatosis type 1 (NF1) predisposes individuals to early and debilitating cardiovascular disease. Loss of function mutations in the NF1 tumor suppressor gene, which encodes the protein neurofibromin, leads to accelerated...
9.
Bessler W, Kim G, Hudson F, Mund J, Mali R, Menon K, et al.
Hum Mol Genet
. 2016 Jan;
25(6):1129-39.
PMID: 26740548
Persons with neurofibromatosis type 1 (NF1) have a predisposition for premature and severe arterial stenosis. Mutations in the NF1 gene result in decreased expression of neurofibromin, a negative regulator of...
10.
Li F, Downing B, Smiley L, Mund J, Distasi M, Bessler W, et al.
Circulation
. 2013 Dec;
129(11):1213-24.
PMID: 24370551
Background: Neurofibromatosis type 1 (NF1) is a genetic disorder resulting from mutations in the NF1 tumor suppressor gene. Neurofibromin, the protein product of NF1, functions as a negative regulator of...